Scientific Sessions 2025  /  Groundbreaking Trials in Cardiometabolic Therapeutics  /  Discussant
Logo

American Heart Association

  77
  0

Final ID:

Discussant

  • Lingvay, Ildiko  ( UT Southwestern Medical Center , Dallas , Texas , United States )
  • Rosenson, Robert  ( MT SINAI SCHOOL MEDICINE , New York , New York , United States )
    • Author Disclosures:
    Ildiko Lingvay: DO have relevant financial relationships ; Research Funding (PI or named investigator):Boehringer Ingelheim:Active (exists now) ; Consultant:Merck:Active (exists now) ; Consultant:Janssen:Active (exists now) ; Consultant:Betagenon:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Consultant:Alveus Therapeutics:Active (exists now) ; Consultant:Altimmune:Active (exists now) ; Consultant:AbbVie:Active (exists now) ; Research Funding (PI or named investigator):Roche:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Active (exists now) ; Research Funding (PI or named investigator):Lilly:Active (exists now) ; Research Funding (PI or named investigator):Dexcom:Active (exists now) | Robert Rosenson: DO have relevant financial relationships ; Research Funding (PI or named investigator):Amgen:Active (exists now) ; Consultant:Intercept Pharmaceuticals:Past (completed) ; Consultant:Eli Lilly:Active (exists now) ; Consultant:Editas Medicine:Past (completed) ; Consultant:CRISPER Therapeutics:Past (completed) ; Consultant:Arrowhead:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Research Funding (PI or named investigator):Shanghai Argo Biopharmaceutical Co.:Active (exists now) ; Research Funding (PI or named investigator):89Bio:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Past (completed) ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Research Funding (PI or named investigator):NIH:Active (exists now) ; Research Funding (PI or named investigator):Merck:Active (exists now) ; Research Funding (PI or named investigator):Eli Lilly:Active (exists now) ; Research Funding (PI or named investigator):Arrowhead:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Groundbreaking Trials in Cardiometabolic Therapeutics

Saturday, 11/08/2025 , 08:30AM - 09:45AM

Late-Breaking Science

More abstracts on this topic:
Discussant: VESALIUS-CV trial

Morris Pamela

DR10624, a First-In-Class, FGF21 Receptor/Glucagon Receptor/GLP-1 Receptor Triple Agonist, Rapidly and Significantly Reduced Triglycerides, Atherogenic Lipids, and Liver Fat in Patients With Severe Hypertriglyceridemia: Primary Results From a Randomized Phase 2 Trial.

Li Jianping, Zhou Zijian, Lv Lingchun, Gan Yulong, Wang Ying, Zhu Chaonan, Xu June, Huang Yanshan, Fang Yongliang, Zhang Long, Fan Yanting, Zhang Shu, Wang Liyun, Qu Yanling, Yin Guotian, Jiang Hongwei

More abstracts from these authors:
How do we SELECT incretin analogues and SUSTAIN their impact? Clinical approaches for short and long-term obesity care

Jastreboff Ania, Lingvay Ildiko

ANGPTL3 inhibitors for reduction of cardiovascular disease risk

Rosenson Robert

You have to be authorized to contact abstract author. Please, Login
Not Available